Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Richard Samulski
Univ of North Carolina Chapel Hill, Department: Genetics
Should you be removed from our database? Contact us at [email protected]. Read more below.
AskBio
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The SFIs of the investigator are related to the funded research since the technology being used in the project has been licensed to the company with which the investigator has multiple relationships.
The Institution has determined that since the technology could be further validated as a result of the research, these financial interests could conflict with project.
Treatment of Peripheral Nervous System Dysfunction in Giant Axonal Neuropathy
Giant axonal neuropathy (GAN) is a rare pediatric neurodegenerative disorder characterized by peripheral neuropathy that includes autonomic and enteric dysfunction. An NIH-sponsored Phase I clinical trial (NCT02362438) is underway to test the safety of intrathecal administration of adeno-associated virus (AAV) carrying the human GAN gene to treat the most severe aspects of GAN, namely motor and sensory neuropathy; however it is unknown what impact this treatment will have across the peripheral nervous system (PNS), and in particular the autonomic and enteric nervous systems. This research will determine effective means of using AAV to deliver gene therapy to specific components of the PNS, findings that are immediately relevant to the ongoing GAN clinical trial and for the development of gene therapies for other disorders characterized by PNS dysfunction.
Filed on February 12, 2016.
Tell us what you know about Richard Samulski's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Richard Samulski”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | AskBio | $0 - $4,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | AskBio | $0 - $4,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | AskBio | $150,000 - $199,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Ask Bio, Inc | $0 - $4,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Ask Bio, Inc | Value cannot be readily determined |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios BioPharmaceutical, | $0 - $4,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios Biopharmaceutical Inc. | $0 - $4,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios Biopharmaceutical Inc. | $0 - $4,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios Biopharmaceutical (askbio), Inc. | $150,000 - $199,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Ask Bio, Inc | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.